Verastem to Present at the Jefferies 2017 Global Healthcare Conference
Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer
patients, today announced that the company will present at the Jefferies 2017 Global Healthcare Conference on Friday, June 9 at
11:00 a.m. ET at the Grand Hyatt in New York City.
A live audio webcast of the presentation will be available on the company’s website at www.verastem.com. An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve
outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and
PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase
3 clinical trial in patients with CLL. In addition, Verastem is developing the FAK inhibitor defactinib, which is
currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment
of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma.
Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity
and reducing cancer stem cells. For more information, please visit www.verastem.com.
Brian Sullivan, 781-292-4214
Director, Corporate Development